MNKD · Mannkind Corp
$3.88
-0.03 (-0.77%)
At close · Jul 29
Market Cap
$1.21B
Shares
308.95M
Mannkind Corp Earnings Call Transcripts
Every quarterly earnings call for Mannkind Corp (MNKD) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼18.8%
$18.89M
−$29.02M
'22 Q2
22-08-09
▲47.8%
$32.83M
−$14.43M
'22 Q3
22-11-08
▲188.1%
$36.06M
−$17.95M
'22 Q4
23-02-23
▲238.8%
$40.63M
−$9.79M
'23 Q1
23-05-09
▲157.3%
$48.61M
−$5.26M
'23 Q2
23-08-07
▲56.1%
$51.25M
$1.72M
'23 Q3
23-11-07
▲62.2%
$58.47M
$1.40M
'23 Q4
24-02-27
▲63.1%
$66.26M
$10.63M
'24 Q1
24-05-08
▲48.9%
$72.39M
−$2.01M
'24 Q2
24-08-07
▲36.7%
$70.08M
$11.55M
'24 Q3
24-11-07
▲31.3%
$76.78M
$7.42M
'24 Q4
25-02-26
▲18.2%
$78.35M
$13.16M
'25 Q1
25-05-08
▲5.7%
$76.53M
$668,000
'25 Q2
25-08-06
▲17.2%
$82.13M
$7.99M
'25 Q3
25-11-05
▲45.8%
$111.95M
−$15.95M
'25 Q4
26-02-26
LATEST
▲15.1%
$90.17M
−$16.62M
'26 Q1
26-05-06
Earnings call
FY26 · Q1
2026-05-06
Mannkind Corp Q1 FY2026 Earnings Call
Confident tone
FURO6 auto-injector
United Therapeutics / Tyvaso DPI
MNKD-201 / nintedanib DPI
Revenue
$90.17M
▲ 15.1% YoY Diluted EPS
$-0.05
▼ 225% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Mannkind Corp Q4 FY2025 Earnings Call
Confident tone
Afrezza growth and pediatric opportunity
Furoscix performance and integration
Pipeline and FDKP technology platform
Revenue
$111.95M*
▲ 45.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Mannkind Corp Q3 FY2025 Earnings Call
Confident tone
Record Q3 Revenue and Commercial Momentum
Afrezza Pediatric Label Expansion
Margin and Cost Considerations
Revenue
$82.13M
▲ 17.2% YoY Diluted EPS
$0.03
▼ 25% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Mannkind Corp Q2 FY2025 Earnings Call
Confident tone
Afrezza / Endocrine (incl. pediatric)
Nintedanib DPI / INFLO Phase II
Blackstone financing & balance sheet
Revenue
$76.53M
▲ 5.7% YoY Diluted EPS
$0.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Mannkind Corp Q1 FY2025 Earnings Call
Confident tone
Endocrine/Afrezza commercial performance
Inhaled nintedanib (MNKD-201) for IPF
Pediatric and label expansion of Afrezza
Revenue
$78.35M
▲ 18.2% YoY Diluted EPS
$0.04
▲ 0% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Mannkind Corp Q4 FY2024 Earnings Call
Confident tone
Afrezza pediatric opportunity
Diabetes / Endocrine business growth
Tyvaso DPI collaboration / United Therapeutics
Revenue
$76.78M*
▲ 31.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Mannkind Corp Q3 FY2024 Earnings Call
Confident tone
Afrezza commercial performance and diabetes
Nintedanib DPI (MNKD-201) for IPF
Clofazamine Inhalation (MNKD-101) Phase 3 in NTM
Revenue
$70.08M
▲ 36.7% YoY Diluted EPS
$0.04
▲ 300% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Mannkind Corp Q2 FY2024 Earnings Call
Confident tone
Afrezza Commercial Growth
INHALE-3 Trial & Endocrine Pipeline
Clofazimine Inhalation Suspension (NTM)
Revenue
$72.39M
▲ 48.9% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Mannkind Corp Q1 FY2024 Earnings Call
Confident tone
Endocrine (Afrezza, V-Go) and diabetes pipeline
Tyvaso DPI royalties and collaboration
Financial performance and balance sheet
Revenue
$66.26M
▲ 63.1% YoY Diluted EPS
$0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Mannkind Corp Q4 FY2023 Earnings Call
Confident tone
Tyvaso DPI royalty and monetization
Pipeline (MNKD-101 clofazimine and MNKD-201)
INHALE-1 and INHALE-3 clinical readouts
Revenue
$58.47M*
▲ 62.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Mannkind Corp Q3 FY2023 Earnings Call
Revenue
$51.25M
▲ 56.1% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Mannkind Corp Q2 FY2023 Earnings Call
Revenue
$48.61M
▲ 157.3% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Mannkind Corp Q1 FY2023 Earnings Call
Revenue
$40.63M
▲ 238.8% YoY Diluted EPS
$-0.04
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Mannkind Corp Q4 FY2022 Earnings Call
Revenue
$36.06M*
▲ 188.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Mannkind Corp Q3 FY2022 Earnings Call
Revenue
$32.83M
▲ 47.8% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Mannkind Corp Q2 FY2022 Earnings Call
Revenue
$18.89M
▼ 18.8% YoY Diluted EPS
$-0.11
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Mannkind Corp Q1 FY2022 Earnings Call
Revenue
$11.99M
▼ 31.2% YoY Diluted EPS
$-0.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Mannkind Corp Q4 FY2021 Earnings Call
Revenue
$12.52M*
▼ 32.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Mannkind Corp Q3 FY2021 Earnings Call
Revenue
$22.21M
▲ 44.7% YoY Diluted EPS
$-0.02
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Mannkind Corp Q2 FY2021 Earnings Call
Revenue
$23.28M
▲ 54% YoY Diluted EPS
$-0.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Mannkind Corp Q1 FY2021 Earnings Call
Revenue
$17.44M
▲ 7.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Mannkind Corp Q4 FY2020 Earnings Call
Revenue
$18.44M*
▲ 15.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Mannkind Corp Q3 FY2020 Earnings Call
Revenue
$15.35M
▲ 5.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Mannkind Corp Q2 FY2020 Earnings Call
Revenue
$15.11M
▲ 0.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Mannkind Corp Q1 FY2020 Earnings Call
Revenue
$16.23M
▼ 7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Mannkind Corp Q4 FY2019 Earnings Call
Revenue
$15.99M
▼ 0.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–26 of 26 earnings calls
Key facts
CIK
899460
CUSIP
56400P706
13F (30d)
52 filings
52 filers
Visit website
Investor relations